Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2021 Financial Results
July 15, 2021 16:01 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, July 15, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
Fate Therapeutics Appoints Mark Plavsic, DVM, PhD, RAC as Chief Technical Officer
June 15, 2021 08:00 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, June 15, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
Fate Therapeutics Highlights Positive Interim Data from its Phase 1 Study of FT516 in Combination with Rituximab for B-cell Lymphoma at 2021 ASCO Annual Meeting
June 04, 2021 07:00 ET
|
Fate Therapeutics, Inc.
8 of 11 Patients in Dose Escalation Cohorts 2 and 3 Achieved Objective Response 6 of 11 Patients Achieved Complete Response, including 2 Patients Previously Treated with Autologous CD19 CAR T-cell...
Fate Therapeutics to Present at Upcoming Investor Conferences
May 25, 2021 16:01 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for...
Fate Therapeutics Announces Encouraging Interim Phase 1 Data for iPSC-derived NK Cell Programs in Relapsed / Refractory Acute Myeloid Leukemia
May 13, 2021 16:01 ET
|
Fate Therapeutics, Inc.
4 of 9 Patients in FT516 Monotherapy Study Achieved Objective Response with Complete Leukemic Blast Clearance in the Bone Marrow 2 Patients in Second Dose Escalation Cohort of FT516 Monotherapy Study...
Fate Therapeutics Reports First Quarter 2021 Financial Results and Highlights Operational Progress
May 05, 2021 16:01 ET
|
Fate Therapeutics, Inc.
IND Application Allowed by FDA for FT538 in Solid Tumors; Clinical Trial to Commence in 2021 Phase 1 Data from FT516 and FT538 Programs in Relapsed / Refractory Acute Myeloid Leukemia to be Featured...
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2021 Financial Results
April 29, 2021 08:00 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, April 29, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development...
Fate Therapeutics Announces Four Presentations at the 2021 ASGCT Annual Meeting
April 27, 2021 16:31 ET
|
Fate Therapeutics, Inc.
Two Oral Presentations to Cover iPSC-derived Cell-based Cancer Immunotherapy Pipeline Company to Host Investor Event on May 13 to Highlight Interim Phase 1 Clinical Data from the Company’s FT516 and...
Fate Therapeutics Announces Retirement of Chief Scientific Officer after 12 Years of Service
March 25, 2021 07:00 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
Fate Therapeutics to Present at Upcoming Investor Conferences
March 08, 2021 07:00 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, March 08, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development...